Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
FXR452 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A07880 | 32325178 | J Ethnopharmacol | Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. | 2020 | Details |
| A08004 | 32282030 | Br Med Bull | Obeticholic acid-a new therapy in PBC and NASH. | 2020 | Details |
| A08115 | 32241197 | Expert Rev Gastroenterol Hepatol | Obeticholic acid for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A08128 | 32237916 | Expert Opin Pharmacother | Current and new pharmacotherapy options for non-alcoholic steatohepatitis. | 2020 | Details |
| A08207 | 32205261 | J Ethnopharmacol | Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor. | 2020 | Details |
| A08228 | 32192487 | Cell Commun Signal | FXR-mediated inhibition of autophagy contributes to FA-induced TG accumulation and accordingly reduces FA-induced lipotoxicity. | 2020 | Details |
| A08246 | 32189432 | J Cell Mol Med | A network pharmacology-based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors. | 2020 | Details |
| A08427 | 32115759 | Hepatology | Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. | 2020 | Details |
| A08555 | 32062620 | J Toxicol Sci | Taurine attenuates hepatic steatosis in a genetic model of fatty liver disease. | 2020 | Details |
| A08711 | 32015483 | Sci Rep | Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. | 2020 | Details |
| A08745 | 32003601 | Am J Physiol Gastrointest Liver Physiol | Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. | 2020 | Details |
| A08782 | 31986416 | Biomed Pharmacother | Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis. | 2020 | Details |
| A08915 | 31940200 | J Med Chem | Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08931 | 31932588 | Nat Commun | SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. | 2020 | Details |
| A08933 | 31931543 | Z Gastroenterol | [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] | 2020 | Details |
| A09076 | 31883408 | Liver Int | Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease. | 2020 | Details |
| A09399 | 31760308 | J Nutr Biochem | Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice. | 2019 | Details |
| A09472 | 31731192 | Biomed Pharmacother | Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease. | 2019 | Details |
| A09527 | 31707624 | Rev Endocr Metab Disord | Dietary lipids, gut microbiota and lipid metabolism. | 2019 | Details |
| A09531 | 31706011 | Pharmacol Res | Combinational applicaton of silybin and tangeretin attenuates the progression of non-alcoholic steatohepatitis (NASH) in mice via modulating lipid metabolism. | 2019 | Details |
| A09568 | 31692390 | Expert Rev Gastroenterol Hepatol | Progress in promising anti-fibrotic therapies. | 2019 | Details |
| A09600 | 31679693 | Biochem Biophys Res Commun | Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice. | 2019 | Details |
| A09623 | 31671697 | Cells | Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression. | 2019 | Details |
| A09626 | 31670489 | ChemMedChem | Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast. | 2019 | Details |
| A09757 | 31622696 | J Hepatol | The gut-liver axis in liver disease: Pathophysiological basis for therapy. | 2019 | Details |
| A09881 | 31576092 | World J Gastroenterol | Zinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α. | 2019 | Details |
| A10041 | 31516268 | J Clin Exp Hepatol | Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. | 2019 | Details |
| A10175 | 31452288 | Phytother Res | Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice. | 2019 | Details |
| A10189 | 31442319 | Hepatology | Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. | 2020 | Details |
| A10227 | 31421115 | Chem Biol Interact | Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. | 2019 | Details |
| A10256 | 31409057 | Cells | iPla2β Deficiency Suppresses Hepatic ER UPR, Fxr, and Phospholipids in Mice Fed with MCD Diet, Resulting in Exacerbated Hepatic Bile Acids and Biliary Cell Proliferation. | 2019 | Details |
| A10276 | 31402538 | Liver Int | CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. | 2019 | Details |
| A10323 | 31388096 | Int J Obes (Lond) | Circulating microbiota-derived metabolites: a "liquid biopsy? | 2019 | Details |
| A10338 | 31384531 | Acta Pharm Sin B | Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. | 2019 | Details |
| A10348 | 31380156 | Curr Hepatol Rep | Pathogenesis of NASH: The Impact of Multiple Pathways. | 2018 | Details |
| A10427 | 31341422 | Mediators Inflamm | Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10456 | 31330134 | Metabolism | AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. | 2019 | Details |
| A10465 | 31325638 | Biochim Biophys Acta Mol Cell Biol Lipids | Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. | 2019 | Details |
| A10510 | 31308634 | Drug Des Devel Ther | The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. | 2019 | Details |
| A10544 | 31293521 | Front Endocrinol (Lausanne) | The Nuclear Receptor-Co-repressor Complex in Control of Liver Metabolism and Disease. | 2019 | Details |
| A10686 | 31236687 | Handb Exp Pharmacol | Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease. | 2019 | Details |
| A10772 | 31201553 | Handb Exp Pharmacol | Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. | 2019 | Details |
| A10776 | 31197565 | Handb Exp Pharmacol | Nonsteroidal FXR Ligands: Current Status and Clinical Applications. | 2019 | Details |
| A10911 | 31129048 | Biochem Pharmacol | A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. | 2019 | Details |
| A10928 | 31117231 | Nutrients | Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. | 2019 | Details |
| A10934 | 31114547 | Front Endocrinol (Lausanne) | Hepatic Gene Expression Profiles Differentiate Steatotic and Non-steatotic Grafts in Liver Transplant Recipients. | 2019 | Details |
| A10975 | 31095863 | Mol Nutr Food Res | Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A11551 | 30847736 | Curr Obes Rep | Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery. | 2019 | Details |
| A11631 | 30811073 | Hepatol Res | Hepatic gene expression in mouse models of non-alcoholic fatty liver disease after acute exercise. | 2019 | Details |
| A11645 | 30807179 | J Proteome Res | Proteomic Analysis Reveals Novel Mechanisms by Which Polychlorinated Biphenyls Compromise the Liver Promoting Diet-Induced Steatohepatitis. | 2019 | Details |
| A11679 | 30792450 | Sci Rep | Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1. | 2019 | Details |
| A11720 | 30778102 | Sci Rep | Identification of FDA-approved drugs targeting the Farnesoid X Receptor. | 2019 | Details |
| A11919 | 30682184 | PLoS One | Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. | 2019 | Details |
| A11924 | 30680167 | Food Sci Nutr | Anti-fibrotic activity of Euglena gracilis and paramylon in a mouse model of non-alcoholic steatohepatitis. | 2018 | Details |
| A11959 | 30668392 | Phytomedicine | Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor. | 2018 | Details |
| A12028 | 30635917 | Br J Pharmacol | Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice. | 2019 | Details |
| A12040 | 30628563 | Proc Nutr Soc | Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis. | 2019 | Details |
| A12145 | 30582898 | Biochem Pharmacol | Developments in bile salt based therapies: A critical overview. | 2018 | Details |
| A12177 | 30573812 | Acta Pharmacol Sin | A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters. | 2018 | Details |
| A12223 | 30556145 | Hepatology | Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A12469 | 30443932 | J Cell Biochem | Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. | 2018 | Details |
| A12521 | 30411635 | Expert Opin Pharmacother | Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. | 2018 | Details |
| A12591 | 30372908 | Biomed Pharmacother | Hepatoprotective effect of bisbenzylisoquinoline alkaloid tiliamosine from Tiliacora racemosa in high-fat diet/diethylnitrosamine-induced non-alcoholic steatohepatitis. | 2018 | Details |
| A12729 | 30314377 | Pharmaceuticals (Basel) | Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A12771 | 30294653 | Cell Mol Gastroenterol Hepatol | Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. | 2018 | Details |
| A12835 | 30261763 | Expert Rev Gastroenterol Hepatol | An update on the recent advances in antifibrotic therapy. | 2018 | Details |
| A12850 | 30257410 | Biomed Pharmacother | Curative effect of arjunolic acid from Terminalia arjuna in non-alcoholic fatty liver disease models. | 2018 | Details |
| A12927 | 30222962 | Gastroenterology | Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. | 2018 | Details |
| A12931 | 30221089 | PeerJ | Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver. | 2018 | Details |
| A12959 | 30208322 | Cell Rep | FXR Inhibits Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome in Hepatocytes and Ameliorates Liver Injury. | 2018 | Details |
| A12961 | 30206765 | J Gastrointest Surg | Concomitant PPARα and FXR Activation as a Putative Mechanism of NASH Improvement after Gastric Bypass Surgery: a GEO Datasets Analysis. | 2018 | Details |
| A12977 | 30200543 | Nutrients | Tomato Juice Supplementation Influences the Gene Expression Related to Steatosis in Rats. | 2018 | Details |
| A12985 | 30196282 | Cell Physiol Biochem | Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF. | 2018 | Details |
| A13137 | 30120929 | Toxicology | Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease. | 2018 | Details |
| A13307 | 30038487 | Drug Des Devel Ther | Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. | 2018 | Details |
| A13345 | 30021122 | Pharmacol Res | Future trends in the treatment of non-alcoholic steatohepatitis. | 2018 | Details |
| A13384 | 30006580 | Int J Obes (Lond) | Zinc alpha2 glycoprotein protects against obesity-induced hepatic steatosis. | 2018 | Details |
| A13388 | 30006135 | Arch Biochem Biophys | Ablation of carotenoid cleavage enzymes (BCO1 and BCO2) induced hepatic steatosis by altering the farnesoid X receptor/miR-34a/sirtuin 1 pathway. | 2018 | Details |
| A13464 | 29959418 | Lab Invest | Characterization of a murine nonalcoholic steatohepatitis model induced by high fat high calorie diet plus fructose and glucose in drinking water. | 2018 | Details |
| A13504 | 29945982 | J Endocrinol | INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function. | 2018 | Details |
| A13591 | 29890650 | Foods | Protection by the Total Flavonoids from Rosa laevigata Michx Fruit against Lipopolysaccharide-Induced Liver Injury in Mice via Modulation of FXR Signaling. | 2018 | Details |
| A13626 | 29866129 | BMC Gastroenterol | Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. | 2018 | Details |
| A13636 | 29860219 | Biomed Pharmacother | Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice. | 2018 | Details |
| A13700 | 29802399 | Sci Rep | Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. | 2018 | Details |
| A13702 | 29800811 | J Nutr Biochem | Synbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse models. | 2018 | Details |
| A13821 | 29743187 | Mol Pharmacol | Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation. | 2018 | Details |
| A13890 | 29706895 | Front Physiol | LiverSex Computational Model: Sexual Aspects in Hepatic Metabolism and Abnormalities. | 2018 | Details |
| A13909 | 29697548 | J Pediatr Gastroenterol Nutr | Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment. | 2018 | Details |
| A14000 | 29649907 | Expert Opin Ther Pat | Farnesoid X receptor modulators 2014-present: a patent review. | 2018 | Details |
| A14172 | 29552625 | Cell Mol Gastroenterol Hepatol | Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). | 2017 | Details |
| A14270 | 29491146 | J Biol Chem | Mice lacking ARV1 have reduced signs of metabolic syndrome and non-alcoholic fatty liver disease. | 2018 | Details |
| A14286 | 29482963 | Nutr Metab Cardiovasc Dis | Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. | 2017 | Details |
| A14321 | 29466845 | Korean J Intern Med | Duodenal Niemann-Pick C1-like 1 expression was negatively correlated with liver X receptor expression in nonalcoholic fatty liver disease. | 2018 | Details |
| A14512 | 29375205 | World J Gastroenterol | INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. | 2018 | Details |
| A14541 | 29361497 | Mol Metab | Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. | 2018 | Details |
| A14663 | 29299759 | Hepatol Int | Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. | 2018 | Details |
| A14705 | 29280057 | Obes Surg | Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model. | 2018 | Details |
| A14782 | 29235014 | Obes Surg | Increased Bile Acid Signals After Duodenal-Jejunal Bypass Improve Non-alcoholic Steatohepatitis (NASH) in a Rodent Model of Diet-Induced NASH. | 2018 | Details |
| A14815 | 29222421 | Sci Rep | The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A14826 | 29216638 | Cell Physiol Biochem | MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1. | 2017 | Details |